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Background/aim: Perioperative FLOT regimen is a standard of care in locally advanced operable gastric and GEJ adenocarcinoma. We
aimed to determine the efficacy, prognostic factors of perioperative FLOT chemotherapy in real-life gastric and GEJ tumors.
Materials and methods: The data of patients who were treated with perioperative FLOT chemotherapy were retrospectively analyzed
from 34 different oncology centers in Turkey. Baseline clinical and demographic characteristics, pretreatment laboratory values,
histological and molecular characteristics were recorded.
Results: A total of 441 patients were included in the study. The median of age our study population was 60 years. The majority of patients
with radiological staging were cT3-4N(+) (89.9%, n = 338). After median 13.5 months (IQR: 8.5–20.5) follow-up, the median overall
survival was NR (95% CI, NR to NR), and median disease free survival was 22.9 (95% CI, 18.6 to 27.3) months. The estimated overall
survival at 24 months was 62%. Complete pathological response (pCR) and near pCR was achieved in 23.8% of all patients. Patients
with lower NLR or PLR have significantly longer median OS (p = 0.007 and p = 0.033, respectively), and patients with lower NLR have
significantly longer median DFS (p = 0.039), but PLR level did not affect DFS (p = 0.062). The OS and DFS of patients with better ECOG
performance scores and those who could receive FLOT as adjuvant chemotherapy instead of other regimens were found to be better.
NLR was found to be independent prognostic factor for OS in the multivariant analysis. At least one adverse event reported in 57.6% of
the patients and grade 3–4 toxicity was seen in 23.6% patients.
Conclusion: Real-life perioperative FLOT regimen in operable gastric and GEJ tumors showed similar oncologic outcomes compared to
clinical trials. Better performance status, receiving adjuvant chemotherapy as same regimen, low grade and low NLR and PLR improved
outcomes in real-life. However, in multivariate analysis, only NLR affected OS.
Key words: FLOT chemotherapy, perioperative treatment, gastric cancer, GEJ tumor, prognostic factor

1. Introduction
Gastric
and
gastroesophageal
junction
(GEJ)
adenocarcinoma is among one of the cancers with
poor prognosis. Application of multimodal treatment
protocols contributes to prognosis by providing local
and systemic tumor control as well as increasing surgical
resectability in patients with locally advanced gastric
and GEJ adenocarcinoma. Survival benefit is tried to be
achieved with adjuvant and neoadjuvant chemotherapy
and radiotherapy. However, the results are still not
satisfactory. The 5-year overall survival (OS) rate with
perioperative chemotherapy is between 36% and 38%
in operable gastric cancers [1,2]. The MAGIC study is
the cornerstone for perioperative chemotherapy [2].
In this study, perioperative ECF (Epirubicin, cisplatin,
5-FU) chemotherapy was compared with surgery alone.
Compared to the surgical group alone, the perioperative
chemotherapy group had significantly higher median OS
and progression-free survival (PFS) (hazard ratio for death,
0.75; 95% CI; p = 0.009, and hazard ratio for progression,
0.66; 95% CI; p < 0.001). FLOT chemotherapy regimen (5FU, leucovorin, oxaliplatin, docetaxel) has been considered
in perioperative treatment because of its better tolerability
and response rates in metastatic disease. It was the choice
of perioperative chemotherapy protocol since 2009. The
FLOT4-AIO Phase 2/3 study is a randomized controlled
study evaluating the efficacy and safety of perioperative
FLOT therapy in locally advanced and operable gastric
and gastroesophageal junction tumors [3]. In this study,
in which approximately 700 patients were randomized
1:1, the median OS compared to the ECF regimen was
50 months and 35 months in favor of the FLOT regimen
with HR:0.77 (95% CI: 0.63 to 0.94). After this dramatic

benefit, perioperative FLOT chemotherapy has become a
standard of care in gastric and GEJ adenocarcinoma at cT2
and higher stages.
Clinical trial results and real-life outcomes may differ
from each other. Because the patients included in the
clinical trial are highly selective patients and results can be
found better than in real-life. Therefore, real-life data have
an important place in confirming clinical trials. The next
step after determining the standard treatment for a disease
is to determine which patients will benefit more from
this treatment. By determining predictive and prognostic
factors, patient selection can be made more accurately, and
which patients’ group will benefit from the treatment can
be predicted and the best treatment option can be offered.
There are several prognostic factors for gastric cancer
[4, 5]. The Memorial Sloan Kettering Cancer Center
nomogram is a model predicting survival for gastric
cancer included age, sex, primary tumor site, tumor size,
histology, number of lymph nodes resected (positive and
negative), and depth of invasion [4]. It was identified 23
potentially relevant prognostic factors and 15 predictive
factors for gastric cancer in a systematic review and
metaanalysis. These included prognostic factors such as T
stage, N stage, weight, hemoglobin value, weight loss, and
predictive factors such as age, sex, T stage, N stage, HER2
overexpression, and histology [6].
There are many studies that have showed inflammation
is the main cause of tumorigenesis [7]. Studies have
shown that inflammation can initiate cancer [8].
Neutrophils, platelets and lymphocytes have important
roles in tumor-associated inflammation. Neutrophils
and platelets increase inflammation, while lymphocytes
can produce inhibitory cytokines and reduce tumor
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cell motility. Therefore, decrease in lymphocyte count
with increase in neutrophile and platelet count may lead
to less immunological response against malignancies
[9]. Neutrophil-lymphocyte ratio (NLR) and plateletlymphocyte ratio (PLR) have been shown to have
significant value, especially in gastrointestinal and lung
cancers [10, 11]. However, the prognostic value of NLR
and PLR is unclear in operable gastric and GEJ cancers
receiving perioperative FLOT chemotherapy.
In this study, we aimed to determine the efficacy of
perioperative FLOT chemotherapy as well as its prognostic
factors, including NLR and PLR, in real-life operable
gastric and gastroesophageal junction tumors in Turkey.
2. Materials and methods
The patients with gastric and gastroesophageal junction
tumors who were treated with perioperative FLOT
chemotherapy were retrospectively analyzed. The data
of the patients was collected from 34 different oncology
centers in Turkey. All patients who started FLOT
chemotherapy as neoadjuvant therapy were included
in the study. FLOT regimen includes 5-FU, leucovorine,
oxaliplatin and docetaxel. They are applied intravenously;
oxaliplatin 85 mg/m2, docetaxel 50 mg/m2, and leucovorin
200 mg/m2 on day 1 and then 5-FU 2600 mg/m2 24 h
infusion, every 2 weeks [3]. The standard perioperative
treatment was four cycle preoperative and four cycle
postoperative applications.
This study was planned as a Turkish Oncology Group
(TOG) study and data were collected from medical
oncology clinics across Turkey. We conducted this study
according to the Declaration of Helsinki (1964) and all
its subsequent amendments. Each investigator provided
signed, written, informed consent before enrolment. And
we started the study after it was found ethically appropriate
at the Ankara City Hospital Ethics Committee meeting on
16/06/2021, with the decision number E2-21-617.
2.1. Data acquisition
The patients baseline clinical and demographic
characteristics, pretreatment laboratory values (complete
blood count, albumin value, tumor marker levels), clinical
and pathological stage, and histological and molecular
characteristics were recorded in the database. Treatment
characteristics (response and toxicity) were noted. NLR
was calculated by dividing the neutrophil count by the
lymphocyte count, and PLR was calculated by dividing
the platelet count by the lymphocyte count. Based on
the median value of NLR and PLR (2.8 for NLR and
167.7 for PLR), it was divided into high and low. Values
below the median value were grouped as low, and others
were grouped as high. Disease progression and survival
information during or after treatment were collected and
used for survival analyses.
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2.2. Inclusion criteria and outcomes
Patients aged 18 years and older, who were diagnosed
with operable gastric or GEJ tumor histopathologically,
and who started perioperative FLOT chemotherapy, were
included in the study regardless of their operation status.
Patients diagnosed between 01 January 2017 and 31
December 2020 were screened. Patients who received at
least one treatment cycle for perioperative purposes were
included in the analysis.
The primary endpoints were overall survival (OS) and
disease free survival (DFS). OS was defined as the time
elapsed between initiation of treatment and death from
any cause. DFS was defined as the time elapsed between
initiation of therapy and radiological disease progression
or death from any cause if there was no progression.
Secondary endpoints were objective response rate (ORR),
pathologic complete response (pCR) rate, and adverse
events. Objective response rate was defined as patients
with complete or partial response radiologically. Adverse
events (AEs) were evaluated according to CTCAE v4.03.
2.3. Statistical analysis
The results of study were obtained through the analysis
of our retrospective database. Statistical analysis was
performed using IBM SPSS statistics, Version 25.0 (SPSS
Inc., Chicago, IL, USA). Continuous variables were
summarized with mean, median, standard deviation, and
interquartile range. Categorical variables were summarized
with absolute frequency and percentages. Differences
between groups were evaluated with the chi-square test.
Quantitative values were expressed as medians with range,
and differences were measured using the Mann–Whitney
U test. Survival was univariately analyzed by the Kaplan–
Meier method with a log-rank test for the comparison of
subgroups. Logistic regression analysis was used to analyze
the effect of multiple variables on survival. p value < 0.05
was considered statistically significant.
3. Results
3.1. Patients and disease characteristics
A total of 441 patients data were analyzed in the study. The
median age of our study population was 60 years (18–85).
The percentages of the disease-subtype according to tumor
location were 46,3% for GEJ, 26,3% corpus, 24% antrum,
3,4% fundus. Of the 338 patients with radiological staging
information, 0.9% were cT1-2/N(-), 4.7% cT1-2/N(+), 4.4%
cT3-4/N(-) and 89.9% cT3-4/N (+). Baseline patient, disease
and treatment characteristics summarized in Table 1.
3.2. Treatment characteristics and survival outcomes
Median number of preoperative and adjuvant FLOT cycles
are 4 (range: 1–12) and 4 (range: 0–8), respectively (Table
1). While 93.7% of the patients could undergo surgery, the
R0 resection rate was 86.6% in the data available (n = 402).
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Of the patients, 6.3% could not undergo surgery. Fifteen
percent (66) of patients received extended neoadjuvant
FLOT regimen more than 4 cycles. The R0 resection rate
in these patients is 69.7%, significantly lower than in other
patients. Twenty-six patients received more than 4 cycles
of FLOT as adjuvant therapy.
After median 13.5 months (IQR: 8.5–20.5) follow-up
the estimated median OS was not reached (NR) (95% CI,
NR to NR), and median disease free survival was 22.9
(95% CI, 18.6 to 27.3) months (Figure 1). The estimated
OS rate at 24 months was 62% (Figure 1).
3.3. Prognostic factors
Complete pathological response (pCR) and near pCR was
achieved in 23.8% of all patients. We identified that pCR is
a predictor of improved overall and disease free survival (p
= 0.033, p = 0.030 for OS and DFS, respectively).
Patients with low NLR or PLR have a longer OS (p =
0.007 and p = 0.033, respectively), and patients with low
NLR have a longer DFS (p = 0.039), but PLR level did not
affect DFS (p = 0.062) (Figures 2A–2B and 2C–2D). The
OS and DFS of patients with better ECOG performance
scores and those who could receive FLOT as adjuvant
chemotherapy instead of other regimens were found

to be better. The effects of the variables on OS and DFS
summarized with details in Table 2.
ORR was found to be 58.7% after neoadjuvant therapy
in patients whose radiological evaluation could be obtained
(n = 133) (Table 3). Relaps occurred after a median of 9.2
months (IQR: 6.2–12.7). The major recurrence site was
peritoneal carcinomatosis (52.5%).
Multivariant logistic regression analysis was performed
to identify the factors that actually effect survival within the
variables. Variables with a p value of less than 0.25 on OS were
included in the analysis. However, the ECOG performance
score, adjuvant chemotherapy status, and clinical stage were
excluded from the analysis because their distribution was
not normal. NLR was found to be independent prognostic
factor for OS in the multivariant analysis of NLR, PLR,
grade, CEA and CA19-9 level (Table 4).
3.4. Safety
At least one adverse event reported in 57.6% of the patients
and grade 3–4 toxicity was seen in 23.6% patients. While
the most common side effect was neutropenia (26.1% any
grade, 11.8% grade 3–4), fatigue was the other common
side effect (9.5% any grade). The most common adverse
events summarized in Table 5.

Figure 1. Kaplan-Meier curves for overall survival and
disease-free survival in all patients.
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Table 1. Patients, disease and treatment characteristics.
No.
Median age of diagnosis, years (range)

% (n = 441)

60 (18–85)

Sex
Female

145

32.9

Male

296

67.1

Gastroesophageal junction

204

46.3

Corpus

116

26.3

Antrum

106

24

Fundus

15

3.4

0–1

398

90.2

2

11

2.5

Unknown

32

7.3

cT-N stage

338

T1/T2 N (–)

3

0.9

T1/T2 N (+)

16

4.7

T3/T4 N (–)

15

4.4

T3/T4 N (+)

304

89.9

Yes

124

28.1

No

218

40.4

Missing

99

22.5

Grade 1

32

7.2

Grade 2

137

31.1

Grade 3

169

38.3

Undifferentiated

18

4.1

Missing

85

19.3

HER2 status

262

Positive

15

5.7

Negative

247

94.3

The median cycle of neoadjuvant FLOT, range

4 (1–12)

The median cycle of adjuvant chemotherapy, range

4 (0–8)

FLOT

298

89

5-FU and -platin

16

4.8

5-FU

6

1.8

Others

15

4.4

Yes

75

17

No

366

83

413

93.7

Location of primary tumor

ECOG Performance Score

Signet cells

Grade

Adjuvant radiotherapy

Surgery
Yes
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Table 1. (Continued).
No

28

Pretreatment median hemoglobine, gr/dL, IQR

12 (10.6–13.7)

Pretreatment median NLR, IQR

2.8 (1.96–3.90)

≥2.8

116

Pretreatment median PLR, IQR

167.7 (119.2–236.3)

≥167.7

117

Pretreatment median CEA, ng/mL, IQR

2.6 (1.18–8.43)

Pretreatment median CA19-9, U/mL, IQR

15.5 (6.4–54)

Pretreatment median albumin, mg/dL, IQR

3.9 (3.6–4.2)

<3

8

6.3

50
50.4

3.5

Figure 2. Kaplan-Meier curves for disease-free survival and overall survival according to NLR high and low (A-B), PLR high and low
(C-D).
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Table 2. Effect of variables on OS and DFS.
Median DFS (95% CI), months

p value

Median OS (95% CI), months

p value

22.9 (19.9 to 25.9)
16.2 (12.4 to 20)

0.039

NR (NR to NR)
23.5 (17.1 to 29.9)

0.007

23 (13.6 to 32.4)
17.7 (16 to 19.5)

0.062

NR (NR to NR)
24.2 (21 to 27.4)

0.033

22.9 (7.2 to 38.6)
20.7 (16.2 to 25.3)

0.440

25.9 (9.9 to 41.9)
NR (NR to NR)

0.317

23.5 (18.8 to 28.3)
5.8 (0 to 13)

0.019

NR (NR to NR)
10 (5.8 to 14.2)

0.001

25.2 (18.8 to 31.6)
22.9 (NR to NR)
21.7 (13.2 to 30.1)
20.7 (14.1 to 27.4)

0.565

NR (NR to NR)
NR (NR to NR)
29.2 (20.8 to 37.5)
NR (NR to NR)

0.445

20.7 (16.8 to 24.7)
NR (NR to NR)

0.184

29.2 (NR to NR)
NR (NR to NR)

0.192

NR (NR to NR)
NR (NR to NR)
18.1 (11.7 to 24.5)
13.8 (3.5 to 24.1)

0.001

NR (NR to NR)
NR (NR to NR)
28.7 (NR to NR)
22.7 (12.8 to 32.5)

0.018

27.3 (NR to NR)
17.4 (7.7 to 27)

0.012

NR (NR to NR)
NR (NR to NR)

0.0042

20.7 (19 to 22.5)
25.1 (19.5 to 30.8)

0.934

28.7 (19.7 to 37.6)
NR (NR to NR)

0.319

NR (NR to NR)
17.9 (14.5 to 21.4)

0.184

NR (NR to NR)
29.2 (21.6 to 36.7)

0.530

27.2 (6 to 48.3)
19.1 (15.6 to22.5)

0.946

NR (NR to NR)
24.2 (19.9 to 28.4)

0.163

13.7 (8 to 19.4)
20.2 (17.2 to 23.2)

0.287

29.2 (7.8 to 50.5)
NR (NR to NR)

0.159

NR (NR to NR)
18.1 (14.3 to 21.8)

0.337

NR (NR to NR)
29.2 (21.5 to 36.9)

0.608

Median NLR
Low
High
Median PLR
Low
Hihg
HER2 status
Positive
Negative
ECOG performance score
0–1
2
Location of primary tumor
Gastroesophageal junction
Corpus
Antrum
Fundus
cT-N stage
T3/T4 (N+)
Others
Grade
Grade 1
Grade 2
Grade 3
Undifferentiated
Adjuvant chemotherapy
FLOT
Others
Adjuvant radiotherapy
Yes
No
Albumin, mg/dL
<3
≥3
CEA, >ULN1 (0-5), ng/mL
Yes
No
CA19-9, >ULN (0-37), U/mL
Yes
No
Hemoglobine, gr/dL
<10
≥10

ULN: Upper limit normal, 2In favor of FLOT.

1
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Table 3. Response rates.
No.

%

ORR (complete and partial response)

78

58.7

Complete response

13

9.8

Partial response

65

48.9

Stable disease

40

30.1

Progressive disease

15

11.3

pCR

52

12.9*

* Among patients who underwent surgery.

Table 4. The multivariate analysis of variables.
Univariate analysis

Multivariate analysis

OR* (95% CI)

p value

OR (95% CI)

p value

NLR

2.21 (1.22–4.01)

0.009

2.60 (1.07–6.36)

0.036

PLR

1.8 (1.00–3.24)

0.050

1.21 (0.51-2.88)

0.667

Grade

2.04 (1.21–3.44)

0.007

1.08 (0.50-2.35)

0.849

CEA

0.54 (0.26–1.10)

0.091

0.48 (0.19-1.17)

0.107

CA19-9

1.26 (0.66–2.42)

0.485

1.54 (0.67-3.54)

0.311

* Odds ratio.

Table 5. The most common AEs during neoadjuvant and adjuvant treatment.
Adverse event

All grades, n (%)

Grade 3–4, n (%)

Any

57.6

23.6

Neutropenia

26.1

11.8

Anemia

19

0.9

Thrombocytopenia

10.2

1.1

Fatigue

9.5

1.6

Diarrhea

8.4

1.6

Neuropathy

8.2

1.4

Stomatitis

4.8

0.2

4. Discussion
Surgery involving D2 lymph node dissection and R0
resection is the only curative treatment option for gastric
and GEJ cancers. Since there is no specific screening
program in most countries, more than half of the patients
are diagnosed at locally advanced stage [12]. Multimodal
treatment options are used to increase the rate of curative
treatment. Perioperative chemotherapy has been used for
many years in locally advanced gastric and GEJ tumors

because of its survey advantage by downstaging the tumor
and reducing the risk of local and distant relapses by
eradicating the micrometastatic disease. For this purpose,
platinum and anthracycline-based chemotherapy was
used most frequently [1, 2].
In the FLOT4-AIO trial, the MAGIC regimen was
compared with the taxane-containing FLOT regimen. The
median OS and DFS was 50 and 30 months, respectively
[3]. And OS at 2 years was 68% and ≤ypT1 was 25%. With
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this study, 5-year survival increased from 35%–40% to
45%. In our study, median OS was not reached and median
DFS was 22.9 months. Estimated OS rate at 2 years was
62% and ≤ypT1 (tumor invades the submucosa following
preoperative chemotherapy) was 26.3%. One reason for the
slightly lower survival compared to the FLOT4-AIO trial
was the inclusion of clinically worse patients (a real-life
classic) and advanced stage. While the rate of patients with
an ECOG performance score of 0–1 in our study was 90%,
this rate was 99% in the FLOT4-AIO study. The other reason
of lower survival was the higher stage of disease. In pivotal
trial of FLOT [3], the rate of patients with clinically T3-4
was 83% and node positive patients was 78%. These rates
were over 94% for both in our study. On the other hand, it
would be expected that more advanced and clinically worse
patients may undergo less surgery; however, a similar rate
of surgery was performed in our study and the FLOT4-AIO
trial (94%). And patients had similar pCR and near pCR
rates (25% vs. 23.8%) in all patients.
In the univariate analysis, we determined that better
ECOG performance score, low grade, continuing adjuvant
chemotherapy as FLOT, and low NLR improved OS and
DFS. PLR did not affect DFS, but patients with low PLR
had longer OS. In the multivariate analysis, we determined
that NLR was independent predictive factors for OS.
NLR is a well-known prognostic factor in multiple
tumors [13, 14]. Higher NLR is associated with worse survival
outcomes [15, 16]. In a metaanalysis of breast cancer, it was
shown that NLR was a prognostic factor for overall survival,
independently of tumor stage [17]. Similarly with NLR,
PLR can be used as a marker for inflammation. Prognostic
features have been demonstrated in many tumors [15, 16]. In
our study, lower NLR and PLR were found to be associated
with better survival, similar to previous studies [15, 16, 18].
This result is important; however, hematological values of
patients may change after neoadjuvant treatment. In a study
published in 2020 including gastric cancer patients receiving
neoadjuvant chemotherapy, higher NLR was related with
worse overall survival when evaluated before neoadjuvant
treatment [19]. In that trial, in the multivariate analysis of
preneoadjuvant treatment values, no variable was found
to be an independent prognostic factor. In addition, in the
combined analysis of inflammatory markers before and
after neoadjuvant treatment, NLR lost its prognostic feature.
In this analysis, receiving FLOT as adjuvant
chemotherapy appeared to be more beneficial for
survival than others. There are conflicting data on this
subject. However, an important observational study
on this subject revealed that it is important to complete
perioperative chemotherapy. The 5-year survival rate in
patients who received both preoperative and postoperative
chemotherapy was 75.8%, while it was 40.3% in those who
received only preoperative treatment [20]. In another study
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with 299 patients, completion of adjuvant chemotherapy
did not show a survival benefit in all patients [21]. However,
in our study, completion of adjuvant chemotherapy was
shown to have a DFS benefit (p = 0.038). The ratio of these
patients is 56.8% of the whole study group.
Median number of preoperative and adjuvant FLOT
cycles are 4 (range: 1–12) and 4 (range: 0–8), respectively.
Fifteen percent (66) of patients received more than 4
cycles of FLOT as neoadjuvant. The R0 resection rate in
these patients was 69.7%, significantly lower than in other
patients. Twenty-six patients received more than 4 cycles
of FLOT as adjuvant therapy. Although there is insufficient
data for the prolonged therapy, these patients were
probably more advanced and had a higher tumor burden.
In the data, it was observed that there were patients with
suspected metastasis at baseline and also inoperable after
4 cycles of neoadjuvant therapy and continued treatment.
HER-2 status, tumor location, disease stage, albumin
and hemoglobin values, and tumor marker levels did not
have any effect on survival, consistent with the literature.
Radiotherapy is used preoperatively and postoperatively
in gastric cancers, especially in GEJ tumors. Although there
is no head-to-head study of perioperative chemotherapy
and adjuvant chemoradiotherapy, radiotherapy is not
recommended in patients treated with perioperative
chemotherapy unless R1-2 resection is performed. In this
study, no difference in survival was found in patients who
received adjuvant radiotherapy compared to those who
did not.
The tolerability and safety profile of the FLOT were
favorable than the clinical trial. The most common AEs
were hematological (neutropenia and anemia) in both our
study and the FLOT4-AIO trial. The most common grade
3–4 side effect was neutropenia with 11.8% in our study
and 51% in the landmark study [3].
This study has several limitations. First, the follow-up
period of the patients included in the study is short because
FLOT regimen commonly used only in last few years.
Therefore, some of the survival data are still immature
but early results of this regimen in real-life is so important
to accept as a standard regimen. Second, some data may
have been missed because the clinical data were obtained
from hospital records. Although it was understood
from the patient files that there was no active infection,
mild infection may not have been noted. Therefore, this
may affect the ratio of NLR and PLR. Third, there is no
antiplatelet agent treatment information that may affect
platelet count and activity (It can affect the PLR). Fourth,
there is no information about steroid therapy (may affect
the blood count); however, this may cause minimal
error because pretreatment steroid use is not common
in Turkey. Fifth, since it is a multicenter study, surgery
was performed by different clinics. This may also have
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affected the results. Finally, there is no information about
microsatellite instability status of patients.
In conclusion, real-life perioperative FLOT regimen in
operable gastric and GEJ tumors showed similar oncologic
outcomes compared to clinical trials. Better performance
status, receiving adjuvant chemotherapy as same regimen,
lower grade and lower NLR and PLR improved outcomes
in real-life.
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